INS and type 2 diabetes mellitus: The majority of T2D patients received metformin (72.8%), angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) (45.2%), and statin therapy (41.9%), while one-third of the T2D patients were treated with insulin or glucagon-like peptide-1 receptor agonist.